Skip to main content
SpringerLink
Log in

Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock

  • Histamine and Kinins
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Soluble phospholipase A2 has been implicated in the pathogenesis of local and systemic inflammatory reactions. Elevated levels of circulating phospholipase A2 (PLA2) correlate with the severity of circulatory collapse and pulmonary dysfunction in gram-negative septic shock. Characterization of septic shock serum PLA2 revealed a calcium-dependent enzyme with absolute 2-acyl specificity with a pH optimum of 7.5. We tested a number of therapeutic agents for their ability to inhibit PLA2 from human septic shock serum. Chloroquine, chlorpromazine, dexamethasone base, dexamethasone sodium phosphate, indomethacin, lidocaine, oleic acid, palmitic acid, promethazine, trans-retinoic acid, rutin and dl-α-tocopherol were all studied over the range of 10−2 to 10−7 M. All agents, with the sole exception of dexamethasone base, inhibited PLA2 activity at concentrations greater than 10−3M. PLA2 inhibition by dexamethasone sodium phosphate was factitious, due to the formation of calcium-phosphate complexes. Of the 11 agents studied, chlorpromazine was the most effective, with an IC50 of 7.5×10−5 M, a membrane concentration achievable within its therapeutic range. Inhibition was non-competitive, with an apparent Ki of 5 nM. Since serum PLA2 levels correlate with mortality in both experimental endotoxemia and clinical gram-negative septic shock, and chlorpromazine was previously shown to improve survival in these conditions, we postulate that its therapeutic efficacy resides at least in part in its PLA2-inhibitory activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. P. Vadas and J. Hay,Involvement of circulating phospholipase A 2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can. J. Physiol. Pharmacol.61, 561–566 (1983).

    PubMed  Google Scholar 

  2. P. Vadas and W. Pruzanski,Role of extracellular phospholipase A 2 in inflammation. Adv. Inflamm. Res.7, 51–59 (1984).

    Google Scholar 

  3. P. Vadas,Elevated plasma phospholipase A 2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med.104, 873–881 (1984).

    PubMed  Google Scholar 

  4. P. Vadas, W. Pruzanski, E. Stefanski, J. Bohnen, R. Mustard, and I. Fraser,The pathogenesis of hypotension in septic shock: the contributory role of circulating phospholipase A 2. N.E.J.M. (submitted).

  5. K. Slotta, J. Vick and N. Ginsberg, Enzymatic and toxic activity of phospholipase A. InToxins of plant and animal origin, p. 401 (Eds. A. de Vries and E. Kochva) Gordon and Breach, New York 1971.

    Google Scholar 

  6. E. Habermann,Beiträge zur pharmacologie von phospholipase A. Arch. Exp. Pathol. Pharmakol.230, 538–546 (1957).

    Google Scholar 

  7. J. Vick and R. Brooks,Pharmacological studies of the major fractions of bee venom.Am. Bee. J. 112, 288–289 (1972).

    Google Scholar 

  8. N. Marsh and B. Whaler,The effects of honey bee venom and two of its constituents, melittin and phospholipase A 2,on the cardiovascular system of the rat. Toxicon18, 427–435 (1980).

    PubMed  Google Scholar 

  9. P. Vadas, E. Stefanski, W. Pruzanski,Characterization of extracellular phospholipase A 2 in rheumatoid synovial fluid. Life Sci.36, 579–587 (1985).

    PubMed  Google Scholar 

  10. P. Patriarca, S. Beckerdite and P. Elsbach,Phospholipases and phospholipid turnover in escherichia coli spheroplsts.Biochim. Biophys. Acta 260, 593–600 (1972).

    PubMed  Google Scholar 

  11. K. Shakir,Phospholipase A2 activity of post-heparin plasma: a rapid and sensitive assay and partial characterization.Anal. Biochem. 114, 64–70 (1981).

    PubMed  Google Scholar 

  12. J. Nishijima, M. Okamoto, M. Ogawa, G. Kosaki, and T. Yamano,Purification and characterization of human pancreatic phospholipase A2 and development of a radioimmunoassay. J. Biochem.94, 137–147 (1983).

    PubMed  Google Scholar 

  13. J. Folch, M. Lees, and G. Stanley,A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem.226, 497–509 (1957).

    PubMed  Google Scholar 

  14. W. Pruzanski and P. Vadas,The role of secretory phospholipases A2 in the pathobiology of disease. Lab. Invest. (accepted for publication).

  15. T. Schroder, E. Kivilaakso, P. Kinnunen and M. Lempinen,Serum phospholipase A 2 in human acute pancreatitis. Scand. J. Gastroenterol.15, 633–636 (1980).

    PubMed  Google Scholar 

  16. T. Nevalainen,The role of phospholipase A in acute pancreatitis. Scand. J. Gastroenterol.15, 641–650 (1980).

    PubMed  Google Scholar 

  17. T. Schroder, M. Lempinen, E. Kivilaakso, and P. Nikki,Serum phospholipase A 2 and pulmonary changes in acute fulminant pancreatitis. Resuscitation10, 79–87 (1982).

    PubMed  Google Scholar 

  18. M. Jain and D. Jahagirdar,Action of phospholipase A 2 on bilayer. Effect of inhibitors.Biochim. Biophys. Acta. 814, 319–326 (1985).

    PubMed  Google Scholar 

  19. G. Blackwell and R. Flower,Inhibition of phospholipase. Brit. Med. Bull.39, 260–264 (1983).

    PubMed  Google Scholar 

  20. P. Vadas, E. Stefanski and W. Pruzanski,Comparative analysis of assays for phospholipase A 2 activity using biomembrane associated and micellar substrates. The influence of albumin. Inflammation10, 183–187 (1986).

    PubMed  Google Scholar 

  21. C. Vigo, G. Lewis and P. Piper,Mechanisms of inhibition of phospholipase A 2. Biochem. Pharmacol.29, 623–627 (1980).

    PubMed  Google Scholar 

  22. H. Kunze, N. Nahas, J. Trayner, and M. Wurl,Effects of local anesthetics on phospholipases. Biochim. Biophys. Acta441, 93–102 (1976).

    PubMed  Google Scholar 

  23. C. Lanni and E. Becker,Inhibition of neutrophil phospholipase A 2 by p-bromophenacyl bromide, nordihydroguaiaretic acid, 5, 8, 11, 14-eicosatetrayenoic acid and quercetin. Int. Arch. Allergy appl. Immunol.76, 214–217 (1985).

    PubMed  Google Scholar 

  24. H. Tykka, E. Vaittinen, K. Mahlberg, J. Railo, P. Pantzar, S. Sarna, and T. Tallberg,A randomized double-blind study using CaNa 2-EDTA, a phospholipase A 2 inhibitor, in the management of human acute pancreatitis. Scand. J. Gastroenterol.20, 5–12 (1985).

    PubMed  Google Scholar 

  25. K. Authi and J. Traynor,Effects of antimalarial drugs on phospholipase A 2. Br. J. Pharmacol.66, 496P (1979).

  26. R. Ballou and W. Cheung,Inhibition of human platelet phospholipase A 2 activity by unsaturated fatty acids. Proc. Natl. Acad. Sci. USA82, 371–375 (1985).

    PubMed  Google Scholar 

  27. C. Douglas and A. Chan,Vitamin E and partially purified phospholipase A 2. Fed. Proc.42, 809 (1985).

    Google Scholar 

  28. C. Fiedler-Nagy, W. Hope, A. Georgiadis, B. Hughes, J. Coffey and A. Welton,Retinoids inhibit the release of arachidonic acid from rat peritoneal macrophages as well as soluble phospholipase A 2 from Naja naja snake venom. Fed. Proc.42, 773 (1985).

    Google Scholar 

  29. R. Franson, D. Eisen, R. Jesse and C. Lanni,Inhibition of highly purified mammalian phospholipases A 2 by non-steroidal anti-inflammatory agents. Biochem. J.186, 633–636 (1980).

    PubMed  Google Scholar 

  30. R. Flower,Macrocortin and the antiphospholipase proteins. Adv. Inflam. Res.8, 1–33 (1984).

    Google Scholar 

  31. P. Ghira, R. Meli, L. Parente and P. Persico,Distinct inhibition of membrane-bound and lysosomal phospholipase A 2 by glucocorticoid-induced proteins. Biochem. Pharmacol.33, 1445–1450 (1984).

    PubMed  Google Scholar 

  32. P. Vadas,The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A 2 activity. Life Sci.30, 155–162 (1982).

    PubMed  Google Scholar 

  33. N. Kato, K. Halprin, S. Matsuo and J. Taylor,Dexamethasone directly inhibits snake venom phospholipase A. Biochem. Biophys. Res. Comm.130, 761–767 (1985).

    PubMed  Google Scholar 

  34. P. Mentz, C. Giebler and W. Forster,Evidence for a direct inhibitory effect of glucocorticoids on the activity of phospholipase A 2 as a further possible mechanism of some actions of steroidal anti-inflammatory drugs. Pharmacol. Res. Comm.12, 817–826 (1980).

    Google Scholar 

  35. P. Seeman,The membrane actions of anesthetics and tranquilizers. Pharmacol. Rev.24, 583–655 (1972).

    PubMed  Google Scholar 

  36. A. Gilman, L. Goodman and A. Gilman,The pharmacological basis of therapeutics. pg 1696 6th edition. Macmillan Publishing Co., New York 1980.

    Google Scholar 

  37. T. Schroder, M. Lempinen, S. Nordling and P. Kinnune,Chlorpromazine treatment of experimental acute fulminant pancreatitis in pigs. Eur. Surg. Res.13, 143–151 (1981).

    PubMed  Google Scholar 

  38. N. Kambara, K. Takagi, T. Satake, S. Sugiyama and T. Ozawa,Mechanism responsible for endotoxin-induced lung microsomal dysfunction in rats. Lung161, 361–368 (1983).

    PubMed  Google Scholar 

  39. D. Hopkins,Frapper fort or frapper doucement: a gramnegative dilemma. Lancet2, 1193–1194 (1978).

    PubMed  Google Scholar 

  40. J. Reilly, A. Compagnon, P. Tournier and H. duBuit,La prevention et le traitement des accidents observes chez les typhiques apres administration de chloromycetine. Ann. Med.55, 5–34 (1954).

    Google Scholar 

  41. R. Clauss and J. Ray,Pharmacologic assistance to the failing circulation.Surg. Gynecol. Obstet. 126, 611–631 (1968).

    PubMed  Google Scholar 

  42. H. Loeb, A. Curz, J. Boswell, R. Pietras, J. Tobin and R. Gunnar.Haemodynamic studies in shock associated with infection. Brit. Heart J.29, 883–894 (1967).

    PubMed  Google Scholar 

  43. H. Loeb, R. Pietras, N. Ninos, J. Tobin and R. Gunnar,Hemodynamic responses to chlorpromazine in patients in shock. Arch. Intern. Med.124, 354–358 (1969).

    PubMed  Google Scholar 

  44. G. Bailey and R. Strub,Gram-negative septic shock: the new approach.South. Med. J. 59, 1327–1332 (1966).

    PubMed  Google Scholar 

  45. R. Dietzman, W. Manax and R. Lillehei,Shock: mechanisms and therapy. Can. Anaes. Soc. J.14, 276–286 (1967).

    Google Scholar 

  46. R. Dietzman, G. Motsay and R. Lillehei,Pharmakologie und praktische Therapie.Internist 12, 103–107 (1971).

    PubMed  Google Scholar 

  47. V. Meyer,Klinik, Pathogenese und Therapie des Schockzustands bei Sepsis durch gramnegative Erreger. Schw. Med. Woch.96, 137–143 (1966).

    Google Scholar 

  48. H. Thoenen, A. Hurlimman, and W. Haefely,On the mode of action of chlorpromazine on peripheral adrenergic mechanisms. Int. J. Neuropharmacol.4, 79–89 (1965).

    Google Scholar 

  49. D. Rosati,Hypotensive side effects of Phenothiazine and their management. Dis. Nerv. Syst.25, 366–369 (1964).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunology Diagnostic and Research Centre, Department of Medicine, The Wellesley Hospital, University of Toronto, 160 Wellesley St. East, M4Y 1J3, Toronto, Ontario, Canada

    P. Vadas MD, PhD., E. Stefanski & W. Pruzanski

Authors
  1. P. Vadas MD, PhD.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Stefanski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Pruzanski
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by grants-in-aid from: The Arthritis Society and the Medical Research Council of Canada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vadas, P., Stefanski, E. & Pruzanski, W. Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock. Agents and Actions 19, 194–202 (1986). https://doi.org/10.1007/BF01966206

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01966206

Keywords

Search

Navigation